We have a pipeline of novel, best-in-class BET inhibitors for the treatment of cancer and other indications with significant unmet need.
Our next generation selective BET inhibitors are generated from our cutting edge BET epigenetic platform. Selective small molecules with strong drug like properties are evolving through an ongoing lead optimization program.
We are interested in exploring strategic collaborations with corporate partners whose capabilities and expertise will supplement ours in advancing our products through the clinic and to the market.
Chief Business Officer
Phone: (415) 470-5600 ext. 617